Skip to main content
Erschienen in: Supportive Care in Cancer 8/2013

01.08.2013 | Original Article

Multidisciplinary care in patients with prostate cancer: room for improvement

verfasst von: Räto T. Strebel, Tullio Sulser, Hans-Peter Schmid, Silke Gillessen, Martin Fehr, Urs Huber, Miklos Pless, Rudolf Morant, Ralph Winterhalder, Richard Cathomas

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

New multimodality treatment approaches for prostate cancer require multidisciplinary management of patients. We aimed to assess the current practices of multidisciplinarity and their possible implications in treatment management in Switzerland.

Methods

In a survey, urologists and medical oncologists in Switzerland were asked to include at least 25 or 15 consecutive patients with the diagnosis of prostate cancer, respectively. Information about treatment patterns and multidisciplinary parameters of these patients was collected retrospectively.

Results

Thirty-seven urologists and 20 oncologists from the French- and German-speaking parts of Switzerland representing 7 out of 11 non-university tertiary centres and 20/10 % of all office-based urologists/oncologists in Switzerland collected data on 1,184 patients. Sixty-five percent of the office-based (16/24 urologists; 6/10 oncologists) and 95 % of the hospital-based (10/11 urologists; 8/8 oncologists) physicians participate in multidisciplinary tumour boards (MTBs). However, only 1.5 % of patients with a new diagnosis of prostate cancer (13 of 883) are discussed at a MTB. Overall, second opinions at diagnosis are requested in 23 % of patients, mainly from radiation oncologists (8.4 %) or fellow urologists (7.4 %). Second opinions are more often requested by urologists who participate at MTBs and in case of advanced stage.

Conclusions

Participation at MTBs is high among Swiss urologists and oncologists in private practice and at non-university tertiary centers. In spite of that only a small minority of patietns with prostate cancer are presented at MTBs.
Literatur
1.
Zurück zum Zitat Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE (2012) The multi-disciplinary management of high-risk prostate cancer. Urol Oncol 30:3–15PubMedCrossRef Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE (2012) The multi-disciplinary management of high-risk prostate cancer. Urol Oncol 30:3–15PubMedCrossRef
2.
Zurück zum Zitat Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209PubMedCrossRef Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209PubMedCrossRef
3.
Zurück zum Zitat Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123PubMedCrossRef Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123PubMedCrossRef
4.
Zurück zum Zitat Payne HA, Gillatt DA (2007) Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int 99:545–553PubMedCrossRef Payne HA, Gillatt DA (2007) Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int 99:545–553PubMedCrossRef
5.
Zurück zum Zitat Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef
6.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583PubMedCrossRef Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583PubMedCrossRef
7.
Zurück zum Zitat Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26:211–218PubMedCrossRef Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26:211–218PubMedCrossRef
8.
Zurück zum Zitat Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19PubMedCrossRef Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19PubMedCrossRef
9.
Zurück zum Zitat Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146–8151PubMedCrossRef Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146–8151PubMedCrossRef
10.
Zurück zum Zitat Jeldres C, Suardi N, Walz J et al (2008) Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol 54:107–116PubMedCrossRef Jeldres C, Suardi N, Walz J et al (2008) Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol 54:107–116PubMedCrossRef
11.
Zurück zum Zitat Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRef Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRef
12.
Zurück zum Zitat Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422PubMedCrossRef Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422PubMedCrossRef
13.
Zurück zum Zitat de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRef de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRef
14.
Zurück zum Zitat de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005PubMedCrossRef de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005PubMedCrossRef
15.
Zurück zum Zitat Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ (2006) The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer 42:2459–2462PubMedCrossRef Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ (2006) The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer 42:2459–2462PubMedCrossRef
16.
Zurück zum Zitat Ko C, Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105:53PubMedCrossRef Ko C, Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105:53PubMedCrossRef
17.
Zurück zum Zitat Boyle FM, Robinson E, Dunn SM, Heinrich PC (2005) Multidisciplinary care in cancer: the fellowship of the ring. J Clin Oncol 23:916–920PubMedCrossRef Boyle FM, Robinson E, Dunn SM, Heinrich PC (2005) Multidisciplinary care in cancer: the fellowship of the ring. J Clin Oncol 23:916–920PubMedCrossRef
18.
Zurück zum Zitat Valicenti RK, Gomella LG, El-Gabry EA et al (2000) The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol 18:188–191PubMed Valicenti RK, Gomella LG, El-Gabry EA et al (2000) The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol 18:188–191PubMed
19.
Zurück zum Zitat Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 6:e5–e10PubMedCrossRef Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 6:e5–e10PubMedCrossRef
20.
Zurück zum Zitat Valdagni R, Albers P, Bangma C et al (2011) The requirements of a specialist prostate cancer unit: a discussion paper from the European School of Oncology. Eur J Cancer 47:1–7PubMedCrossRef Valdagni R, Albers P, Bangma C et al (2011) The requirements of a specialist prostate cancer unit: a discussion paper from the European School of Oncology. Eur J Cancer 47:1–7PubMedCrossRef
21.
Zurück zum Zitat Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRef Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRef
22.
Zurück zum Zitat Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M (2010) Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58:831–835PubMedCrossRef Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M (2010) Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58:831–835PubMedCrossRef
23.
Zurück zum Zitat Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527PubMedCrossRef Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527PubMedCrossRef
24.
Zurück zum Zitat Ganswindt U, Stenzl A, Bamberg M, Belka C (2008) Adjuvant radiotherapy for patients with locally advanced prostate cancer—a new standard? Eur Urol 54:528–542PubMedCrossRef Ganswindt U, Stenzl A, Bamberg M, Belka C (2008) Adjuvant radiotherapy for patients with locally advanced prostate cancer—a new standard? Eur Urol 54:528–542PubMedCrossRef
25.
Zurück zum Zitat Kibel AS (2005) An interdisciplinary approach to treating prostate cancer. Urology 65(6 Suppl):13–18PubMedCrossRef Kibel AS (2005) An interdisciplinary approach to treating prostate cancer. Urology 65(6 Suppl):13–18PubMedCrossRef
26.
Zurück zum Zitat Hamilton AS, Albertsen PC, Johnson TK et al (2011) Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 107:576–584PubMedCrossRef Hamilton AS, Albertsen PC, Johnson TK et al (2011) Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 107:576–584PubMedCrossRef
27.
Zurück zum Zitat Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401PubMedCrossRef Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401PubMedCrossRef
28.
Zurück zum Zitat Aizer AA, Paly JJ, Zietman AL et al (2012) Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 30:3071–3076PubMedCrossRef Aizer AA, Paly JJ, Zietman AL et al (2012) Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 30:3071–3076PubMedCrossRef
Metadaten
Titel
Multidisciplinary care in patients with prostate cancer: room for improvement
verfasst von
Räto T. Strebel
Tullio Sulser
Hans-Peter Schmid
Silke Gillessen
Martin Fehr
Urs Huber
Miklos Pless
Rudolf Morant
Ralph Winterhalder
Richard Cathomas
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1791-x

Weitere Artikel der Ausgabe 8/2013

Supportive Care in Cancer 8/2013 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.